Adding Chemotherapy for a Patient Receiving ADT + an ARPI

Evan Y. Yu, MD, discusses how adding chemotherapy to a doublet regimen for metastatic hormone-sensitive prostate cancer may be considered on an as-needed basis, particularly for patients with high disease burden or rapid progression, while carefully weighing the potential benefits and risks of intensifying therapy.

EP: 1.Introduction & Case 1 Presentation: mHSPC

EP: 2.Newly diagnosed Diagnosed mHSPC: Goals of Therapy

EP: 3.Newly Diagnosed mHSPC: First-Line Treatment Options

EP: 4.Newly Diagnosed mHSPC: Androgen Receptor Pathway Inhibitor Selection

EP: 5.Case 1 Presentation (cont): mHSPC

EP: 6.Phase 3 ARANOTE Study of ADT + Darolutamide

EP: 7.Phase 3 ARANOTE Study of ADT + Darolutamide: Safety

EP: 8.mHSPC: Applying Data Toward Treatment Decision-Making

Now Viewing

EP: 9.Adding Chemotherapy for a Patient Receiving ADT + an ARPI

EP: 10.Case 2 Presentation: mCRPC

Video content above is prompted by the following:

Would you consider adding chemotherapy to a doublet regimen on an as-needed basis?

Recent Videos